{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:07:45Z","timestamp":1789556865490,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To estimate the live-birth rate per in vitro fertilization (IVF) cycle and after cumulative infertility treatment among patients with anti-m\u00fcllerian hormone (AMH) levels of 0.3 ng\/mL or lower.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study at a single academic center of patients with infertility and AMH levels of 0.3 ng\/mL or lower who initiated one or more IVF cycles (2013\u20132019). Exclusion criteria included prior chemotherapy, hormonal contraceptive use within 3 months of AMH level measurement, and severe male factor infertility. Patients were stratified by Society for Assisted Reproductive Technology (SART) age group. The primary outcome was live-birth rate per IVF cycle. Live-birth outcomes were compared with the 2018 SART National Summary Report for live births per single intended oocyte retrieval, with proportion difference (PD) and 95% CI reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>A total of 978 patients were included. The median (interquartile range) number of cycles initiated was 2 (1\u20133). With the first initiated cycle, the live-birth rate for those with AMH levels of 0.3 ng\/mL or lower was significantly lower in each age category compared with the SART live-birth rate per single initiated cycle (younger than 35 years: 26.2% vs 55.6%, PD 29.4%, 95% CI 20.9\u201337.9%; 35\u201337 years: 15.9% vs 40.8%, PD 24.9%, 95% CI 19.0\u201330.9%; 38\u201340 years: 12.6% vs 26.8%, PD 14.3%, 95% CI 10.2\u201318.3%; 41\u201342 years: 4.7% vs 13.4%, PD 8.7%, 95% CI 5.9\u201311.6%; older than 42 years: 1.2% vs 4.1%, PD 2.9%, 95% CI 1.5\u20134.3%). In patients aged 35\u201337, 38\u201340, 41\u201342, and older than 42 years, the cumulative live-birth rate after up to three initiated cycles was comparable with the SART live-birth rate per single initiated cycle but remained significantly lower in patients younger than age 35 years (PD 16.8%, 95% CI 7.3\u201326.2%). After all treatments were included (cumulative IVF, ovulation induction, and unassisted cycles), live-birth rates were similar to SART live-birth rates per single initiated cycle in all age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Compared with national outcomes, patients with AMH levels of 0.3 ng\/mL or lower had a significantly lower chance of live birth after their first initiated cycle. However, the cumulative live-birth rate after up to three initiated cycles was comparable with national live-birth outcomes per single initiated cycle in patients aged 35 years or older. In patients younger than age 35 years, only when all IVF and non-IVF treatment cycles were included did the cumulative live-birth rate become comparable with the national rate per single IVF cycle.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000004895","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:02:34Z","timestamp":1665075754000},"page":"743-750","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Live-Birth Outcomes Among Women With Infertility and Anti-M\u00fcllerian Hormone Levels of 0.3 ng\/mL or Lower"],"prefix":"10.1097","volume":"140","author":[{"given":"Phillip A.","family":"Romanski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Gelvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bortoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zev","family":"Rosenwaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hey-Joo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/molehr\/gah015","article-title":"Anti\u2010m\u00fcllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment","volume":"10","author":"Weenen","year":"2004","journal-title":"Mol Hum Reprod"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/humupd\/dmt062","article-title":"The physiology and clinical utility of anti-m\u00fcllerian hormone in women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2011-3032","article-title":"Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women","volume":"97","author":"Freeman","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1471-0528.2005.00670.x","article-title":"Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?","volume":"112","author":"Muttukrishna","year":"2005","journal-title":"BJOG"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1093\/humrep\/17.12.3065","article-title":"Serum anti-m\u00fcllerian hormone levels: a novel measure of ovarian reserve","volume":"17","author":"van Rooij","year":"2002","journal-title":"Hum Reprod"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.fertnstert.2015.03.019","article-title":"Diagnostic evaluation of the infertile female: a committee opinion","volume":"103","year":"2015","journal-title":"Fertil Steril"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.fertnstert.2013.12.039","article-title":"Value of antim\u00fcllerian hormone as a prognostic indicator of in vitro fertilization outcome","volume":"101","author":"Reichman","year":"2014","journal-title":"Fertil Sterility"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.2017.14588","article-title":"Association between biomarkers of ovarian reserve and infertility among older women of reproductive age","volume":"318","author":"Steiner","year":"2017","journal-title":"JAMA"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10815-016-0675-7","article-title":"IVF results in patients with very low serum AMH are significantly affected by chronological age","volume":"33","author":"Revelli","year":"2016","journal-title":"J Assist Reprod Genet"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1472-6483(10)60892-9","article-title":"M\u00fcllerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF","volume":"14","author":"Nakhuda","year":"2007","journal-title":"Reprod BioMedicine Online"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jim.2010.08.011","article-title":"Development of a second generation anti-m\u00fcllerian hormone (AMH) ELISA","volume":"362","author":"Kumar","year":"2010","journal-title":"J Immunological Methods"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.fertnstert.2021.02.007","article-title":"Duration, recency, and type of hormonal contraceptive use and antim\u00fcllerian hormone levels","volume":"116","author":"Bernardi","year":"2021","journal-title":"Fertil Sterility"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12958-016-0143-3","article-title":"Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA","volume":"14","author":"Pearson","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"R19-20260916","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/humrep\/der134","article-title":"Live birth chances in women with extremely low-serum anti-mullerian hormone levels","volume":"26","author":"Weghofer","year":"2011","journal-title":"Hum Reprod"},{"key":"R20-20260916","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.fertnstert.2015.10.004","article-title":"Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antim\u00fcllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012\u20132013","volume":"105","author":"Seifer","year":"2016","journal-title":"Fertil Sterility"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/humupd\/dmp036","article-title":"Anti-m\u00fcllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)","volume":"16","author":"La Marca","year":"2010","journal-title":"Hum Reprod Update"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0015-0282(01)03201-0","article-title":"Early follicular serum m\u00fcllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles","volume":"77","author":"Seifer","year":"2002","journal-title":"Fertil Sterility"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.rbmo.2015.06.015","article-title":"Assessing ovarian response: antral follicle count versus anti-m\u00fcllerian hormone","volume":"31","author":"Fleming","year":"2015","journal-title":"Reprod BioMedicine Online"},{"key":"R24-20260916","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.fertnstert.2015.12.003","article-title":"Antim\u00fcllerian hormone and pregnancy loss from the effects of aspirin in gestation and reproduction trial","volume":"105","author":"Zarek","year":"2016","journal-title":"Fertil Sterility"},{"key":"R25-20260916","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.fertnstert.2016.02.020","article-title":"Predictors of pregnancy and live birth in couples with unexplained infertility after ovarian stimulation\u2013intrauterine insemination","volume":"105","author":"Hansen","year":"2016","journal-title":"Fertil Sterility"},{"key":"R26-20260916","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5935\/1518-0557.20170035","article-title":"The predictive value of serum concentrations of anti-m\u00fcllerian hormone for oocyte quality, fertilization, and implantation","volume":"21","author":"Borges","year":"2017","journal-title":"JBRA Assist Reprod"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00404-017-4453-2","article-title":"Anti-mullerian hormone (AMH) and embryo quality assessed by time-lapse imaging (TLI): a cross-sectional observational study","volume":"296","author":"Bhide","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.fertnstert.2020.10.051","article-title":"Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity","volume":"115","author":"Jaswa","year":"2021","journal-title":"Fertil Steril"},{"key":"R29-20260916","doi-asserted-by":"crossref","DOI":"10.1016\/j.rbmo.2022.04.006","article-title":"Age-specific blastocyst conversion rates in embryo cryopreservation cycles","author":"Romanski","year":"2022","journal-title":"Reprod BioMed Online"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/humrep\/deu032","article-title":"Preconception stress increases the risk of infertility: results from a couple-based prospective cohort study\u2014the LIFE study","volume":"29","author":"Lynch","year":"2014","journal-title":"Hum Reprod"},{"key":"R31-20260916","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.fertnstert.2017.05.008","article-title":"Psychological and emotional concomitants of infertility diagnosis in women with diminished ovarian reserve or anatomical cause of infertility","volume":"108","author":"Nicoloro-SantaBarbara","year":"2017","journal-title":"Fertil Sterility"},{"key":"R32-20260916","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.fertnstert.2016.03.006","article-title":"Addressing the needs of fertility treatment patients and their partners: are they informed of and do they receive mental health services?","volume":"106","author":"Pasch","year":"2016","journal-title":"Fertil Sterility"},{"key":"R33-20260916","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1001\/jama.295.12.1374","article-title":"Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure","volume":"295","author":"Schmidt","year":"2006","journal-title":"JAMA"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:00:59Z","timestamp":1789556459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004895","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"assertion":[{"value":"2022-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}